About US
Contact us
-
Johnson & Johnson runs into vaccine supply issues in Europe, threatening second-quarter delivery pledge: ReutersJohnson & Johnson execs have assured investors and officials that the company is "comfortable" hitting its vaccine delivery targets. But with its U.S. rollout underway,the pharma gianthas run int2021/3/10
-
Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?First it was heart disease, now it’s non-small cell lung cancer (NSCLC). Novartis can’t seem to make its canakinumab injection work outside immunology, where the drug’s currently sold as Ilaris. The2021/3/10
-
Roche is gearing up to knock down an Irish plant—and it's complicatedUnable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed f2021/3/8
-
U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warnsThe U.S.' move to lock up raw materials and supplies forPfizer's COVID-19 vaccine could spell trouble for manufacturers working on other shots around the globe. The world’s largest vaccine maker by v2021/3/8
-
"Noble" an Aptar Pharma Company Launches Human Factors Engineering Services2021/3/3
-
3-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real-world data back first vaccineAs Pfizer and BioNTech start testing whether a third dose of their COVID-19 shot can help fend off new coronavirus variants, a massive real-world study has confirmed that its first, two-dose regimen2021/3/1
-
Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktailAs U.S. officials look to ramp up COVID-19 vaccinations heading into March, they’re not overlooking another pandemic-fighting tool. Eli Lilly on Fridayscoreda government supply deal for its newly aut2021/3/1
-
Bristol Myers, hot off Breyanzi nod, plots new cell therapy factory in MassachusettsBristol Myers Squibb, freshly armed with an approval for its CAR-T lymphoma therapy Breyanzi, is making a major cell therapy manufacturing play. The company isbuilding outa new244,000-square-foot cel2021/2/25
-
Catalent continues cell and gene therapy push with deal for Belgian CDMOCatalent's Belgian manufacturing foothold is widening, as the company moves to acquire yet another cell and gene therapy CDMO in the area. Catalent locked in a deal tobuy 100% of the shares of2021/2/25
-
AbbVie, Eli Lilly lead Big Pharma's 2020 market cap growth as Merck, Gilead lagCOVID-19 products aren’t guarantees of market cap growth at biopharma companies these days—and a lack of them doesn’t deprive a drugmaker, either—if a year-end comparison between 2020 and 2019 is a2021/2/23